Eli Lilly's tirzepatide is off FDA's shortage list
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the FDA said in a recent court filing.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss.
Mounjaro is more effective for weight loss than Ozempic—how does it work? And why does it cost so much?
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
Monthly Prescribing Reference5h
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
UK's weight loss jab Mounjaro might help people get back to work: All about it
The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and ...
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
devdiscourse1d
Tirzepatide: A Potential Game-Changer in Tackling Long-Term Sickness
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Trade group sues FDA over ending Mounjaro/Zepbound shortage
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could ...